



Press release

AI tool jointly developed by Hadassah Medical Center – SHL Telemedicine – Hebrew University

Prediction of future life-threatening cardiac events based on SHL ECG devices, including SmartHeart™ technology, enabling performing a remote full 12 Lead ECG by any person

Tel Aviv / Zurich, 2 November 2020 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN), a world leader in the field of portable hospital quality FDA cleared full ECG (12 Lead) for personal use, and the Hebrew University of Jerusalem, through Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., and Hadassah Medical Center, through Hadasit Medical Research and Development Services Ltd. - today announced an agreement to develop an Artificial Intelligence - AI tool for predicting future life-threatening cardiac events based on full 12 Lead ECG monitoring.

According to the agreement, the parties will cooperate in the development of the AI tool with chief researchers from the cardiology department at Hadassah Medical Center and Dr. Yuval Binjamini from the Department of Statistics and Data Science at the Hebrew University of Jerusalem.

Among the team of researchers from the Cardiology Department at Hadassah Ein Kerem Medical Center, are Dr. Yitschak Biton, Prof. David Luria and Dr. Orr Tomer, collaborating with Dr. Yuval Binjamini from the Department of Statistics and Data Science at the Hebrew University, using elite technology which includes artificial intelligence (neural networks) to create tools for predicting future life-threatening cardiac events based on full 12 Lead ECG. The system will use BIG DATA aggregated by SHL Telemedicine unique technology and is expected to detect within milliseconds markers that are hidden from the human eye. The use of the AI tool will enable risk stratification and to effectively and quickly identify patients who are at risk to enable life-saving treatment.

Dr. Yitschak Biton, senior cardiologist at Hadassah: "This AI tool will enable quick and early detection of people who need treatment due to predicted cardiac events. Wherever the patient undergoes an ECG, the system will be able to detect and alert for a life-threatening condition. Using such a system will make it possible to provide early life-saving treatment quickly."

"The medical world is moving towards the adaption of artificial intelligence - AI to predict future risks and preventive medicine in the healthcare fields," said Erez Nachtomy, CEO of SHL Telemedicine. "SHL has unique FDA-approved and patented SmartHeart™ technology for performing full 12 Lead ECG, anytime and from anywhere, with which it is possible to integrate AI tools, such as the one developed in this framework of collaboration with Hadassah Medical Center and the Hebrew University of Jerusalem. Along with our operations in Israel, we are currently accelerating a significant expansion of the use of our technology due to a fundamental need following COVID-19 as well as changing regulatory environment in Germany and the US supporting the shift to remote services becoming standard of care. These opportunities in the German and US markets are very significant for SHL."



For further information please contact:

Martin Meier-Pfister, IRF, Phone: +41 43 244 81 40, shl@irf-reputation.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit our web site at www.shl-telemedicine.com.

About Yissum

Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it is the third company of its kind to be established and serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum's mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. Yissum has registered over 10,750 patents covering 3,000 inventions; licensed over 1,050 technologies and has spun out more than 150 portfolio companies implementing cooperation agreements with leading international companies. For further information please visit www.yissum.co.il.

About Hadasit

Hadasit is the technology transfer company of Hadassah Medical Centers in Jerusalem. Hadasit mission is to transform the cutting-edge research coming out of Hadassah Medical Center into marketable medical technologies. Hadasit turns ground-breaking ideas into viable products and services that can change the world and better humanity. Hadasit spins off companies, licenses technologies, and collaborates with leading international companies and research facilities. Its portfolio includes more than 250 families of active patents which have yielded numerous medical and commercial breakthroughs. This includes the blockbuster drug Doxil which was invented together with the Hebrew University. Developed in cooperation with Johnson & Johnson, the drug is used as part of chemotherapy treatment for ovarian and breast cancers. For further information please visit www.hadasit.org.il.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.